News | August 25, 2010

AGA Medical Files Suit Against W.L. Gore Alleging Patent Infringement

The Gore Helex septal occluder.

August 25, 2010 – Alleging infringement of a patent for its transcatheter cardiac septal occluder devices, AGA Medical Holdings Inc. said it filed a lawsuit against W.L. Gore & Associates.

AGA alleges Gore is infringing its U.S. Patent No. 5,994,738, which covers certain Amplatzer transcatheter occlusion products for the treatment of structural heart defects. AGA is seeking damages against Gore and a permanent injunction prohibiting them from manufacturing and selling the Gore Helex Septal Occluder both in the United States and abroad.

AGA Amplatzer occlusion devices offer minimally invasive, transcatheter treatments in cardiac defect closure. AGA has occlusion devices approved to close seven different structural heart defects.

The company has been a market leader in this field, but its market share has been seriously challenged by Gore’s Helex device.

For more information: www.amplatzer.com, www.goremedical.com

Related Content

Gore Cardioform ASD Occluder Receives FDA Approval
Technology | Structural Heart Occluders | June 10, 2019
W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s) premarket approval (PMA)...
Le Bonheur Children's Hospital Implants First Abbott Amplatzer Piccolo Occluder
News | Structural Heart Occluders | February 13, 2019
Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo Occluder, the world's...
FDA Approves Abbott's Amplatzer Piccolo Occluder
News | Structural Heart Occluders | January 16, 2019
Abbott announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo Occluder to treat patent...
FDA Approves Gore Cardioform Septal Occluder for PFO Closure Prevent Recurrent Ischemic Stroke
Technology | Structural Heart Occluders | April 03, 2018
April 3, 2018 — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen oval
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders | February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
Overlay Init